Data-Driven Decision Support in Obesity Management Commission: enabling more equitable and personalized obesity care

Paul W. Franks / nature - Nature Medicine, Published online: 12 May 2026; doi:10.1038/s41591-026-04363-0Announced in this Comment and in collaboration with Nature Medicine is the convening of the Data-Driven Decision Support in Obesity Management Commission, to promote adequate sc…

AI Summary: A phase 1/2 study of CRISPR‑Cas9 CD33‑deleted allogeneic hematopoietic cell transplantation followed by gemtuzumab ozogamicin maintenance reports encouraging early signals in AML. The gene‑editing approach aims to protect donor cells from CD33‑targeted therapy, potentially enabling safer post‑transplant maintenance and offering a novel strategy to marry cellular engineering with targeted antibody therapy.

• CD33‑targeted transplant and post‑transplant maintenance (4)
• Safety and ethical scrutiny of gene editing and gene therapy (3)
• Scaling cell therapy: accreditation and expanding CAR indications (3)
• All Other Stories

CD33‑targeted transplant and post‑transplant maintenance

Safety and ethical scrutiny of gene editing and gene therapy

Scaling cell therapy: accreditation and expanding CAR indications

All Other Stories